2型糖尿病合并慢性肾脏病的联合药物治疗:证据向临床实践的转化
2型糖尿病(T2DM)患者中约30%-40%发生慢性肾脏病(CKD),同时增加终末期肾病和心血管风险。过去25年,SGLT2抑制剂、非甾体类盐皮质激素受体拮抗剂、GLP-1受体激动剂及RAS阻断剂等药物通过平行降低肾脏和心血管风险,改善了生存并减少透析启动。近期临床试验证据支持针对不同病理生理通路的联合药物治疗。
要点
- T2DM合并CKD患者应同时评估肾脏和心血管风险,高危者需强化联合治疗。
- SGLT2抑制剂、非甾体类MRA、GLP-1RA与RAS阻断剂联合可协同降低肾心风险。
- 联合治疗可延缓进展至终末期肾衰竭,减少透析启动并改善生存。
核心结论
- 针对不同病理生理通路的联合药物治疗可平行降低T2DM合并CKD患者的肾脏和心血管风险,改善生存并减少透析启动。
研究设计与样本
- 综述性文章,总结过去25年T2DM合并CKD药物治疗进展及近期临床试验证据。
主要发现
- T2DM患者中CKD患病率约30%-40%,CKD增加终末期肾病、心血管风险和早逝风险。
- SGLT2抑制剂、非甾体类MRA、GLP-1RA及RAS阻断剂(ACEI或ARB)可平行降低肾脏和心血管风险。
- 联合治疗使高危患者生存改善、心血管事件减少,并因延缓进展至终末期肾衰竭而减少透析启动。
临床怎么用
- 对T2DM合并CKD患者,尤其是高危者,可考虑联合使用SGLT2抑制剂、非甾体类MRA、GLP-1RA及RAS阻断剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) is a dual threat, imposing not only increased risk for end-stage renal disease but also substantially increasing cardiovascular risk and premature mortality. Its prevalence is staggering, affecting approximately 30%-40% of all patients with T2DM. Fortunately, advances in pharmacotherapies over the past 25 years, including sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists, together with blockade of renin-angiotensin aldosterone system activation with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have transformed the clinical management of T2DM and CKD. By providing parallel reductions in both renal and cardiovascular risk, patients with T2DM and CKD (especially those at higher risk) experience improved survival, fewer cardiovascular events and require less initiation of dialysis as a result of delayed progression to end-stage renal failure. Recent evidence from clinical trials in T2DM and CKD supports simultaneous use of combinatory pharmacotherapies targeting distinct mechanistic pathophysiological pathways.
引用
- Lovshin JA. Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice. Nephrol Dial Transplant. 2026. PMID: 42611042. doi:10.1093/ndt/gfag136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。